Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Oncolytic Virus · CG-0070

Gene therapy (Adenoviral vector)

Phase 2/3 Most advanced trial (none active)
1 Registered trials

What is Oncolytic Virus?

CG0070 is an adenoviral vector carrying GM-CSF expression, given intravesically into the bladder. It is studied in transitional cell carcinoma of the bladder, including carcinoma in situ.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CG-0070, GM-CSF expression, adenoviral vector
Drug type
Gene therapy (Adenoviral vector)
Therapy area
Oncology
In trials of
CGON
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
THP9ML4NTZ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01438112 Phase 2/3 Transitional Cell Carcinoma Terminated CGON

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Bladder CancerCarcinoma in SituCarcinoma in Situ Concurrent With Papillary TumorsTransitional Cell Carcinoma

Sources

Updated Nov 8, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.